Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 11 September 2018 Biocartis Creates New Warrant Plan Regulated information 6 September 2018 Biocartis Announces H1 2018 Results Regulated information 3 September 2018 Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla Platform in China Inside information Regulated information 30 August 2018 Biocartis Announces 2018 Half-Year Results on 6 September 2018 Regulated information 28 August 2018 Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy Non-regulated information 31 July 2018 Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) Non-regulated information 17 July 2018 Biocartis launches innovative Idylla™ MSI Assay Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market Non-regulated information 27 June 2018 Study Reviewing 2,500 Performed Idylla™ Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods Non-regulated information 29 May 2018 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 28 May 2018 Study Demonstrates Ability of Idylla™ EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests Non-regulated information Pagination First page « First Previous page ‹‹ … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Next page ›› Last page Last »